SNBIF (SanBio Co) Beta: -0.3261 (As of Jul. 09, 2026)


SNBIF SanBio Co Ltd SNBIF
22 GF Score
Price $16.45
! 1 Warning Sign
View Full Analysis

What is SanBio Co Beta?

SanBio Co SNBIF 22 Beta is -0.3261 as of Jul. 09, 2026. GuruFocus rates SNBIF with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-09), SanBio Co's Beta is -0.3261.


SanBio Co  (OTCPK:SNBIF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


SanBio Co Beta Related Terms


SanBio Co Beta Historical Data

* Premium members only.

The historical data trend for SanBio Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SanBio Co Beta Chart

SanBio Co Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.79 -0.42 -0.46 -0.36 -0.39

SanBio Co Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.37 -0.68 -0.39 -0.32

SNBIF vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, SanBio Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Beta distribution charts can be found below:

* The bar in red indicates where SanBio Co's Beta falls into.


SNBIF
22GF Score
SanBio Co Ltd SNBIF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SanBio Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.3261 mean?
SanBio Co (SNBIF) has a Beta of -0.3261 as of Jul. 09, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for SanBio Co and its competitors.
Is SanBio Co's Beta too high?
SanBio Co's current Beta is -0.3261. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Beta compare to VRTX and REGN?
SanBio Co's Beta of -0.3261 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for SanBio Co and its competitors. SanBio Co's current Beta is -0.3261. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (SNBIF) has a current Beta of -0.3261. The current Beta is -0.3261. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For SanBio Co (SNBIF), the current Beta is -0.3261 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SanBio Co Business Description

Other Exchanges 4592:Japan
Address 8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score

Get the complete analysis for SNBIF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.45
Price